Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases
- PMID: 18266119
- PMCID: PMC2556190
- DOI: 10.1080/13506120701815324
Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases
Abstract
Deposition of immunoglobulin light chains is a result of clonal proliferation of monoclonal plasma cells that secrete free immunoglobulin light chains, also called Bence Jones proteins (BJP). These BJP are present in circulation in large amounts and excreted in urine in various light chain diseases such as light chain amyloidosis (AL), light chain deposition disease (LCDD) and multiple myeloma (MM). BJP from patients with AL, LCDD and MM were purified from their urine and studies were performed to determine their secondary structure, thermodynamic stability and aggregate formation kinetics. Our results show that LCDD and MM proteins have the lowest free energy of folding while all proteins show similar melting temperatures. Incubation of the BJP at their melting temperature produced morphologically different aggregates: amyloid fibrils from the AL proteins, amorphous aggregates from the LCDD proteins and large spherical species from the MM proteins. The aggregates formed under in vitro conditions suggested that the various proteins derived from patients with different light chain diseases might follow different aggregation pathways.
Figures








Similar articles
-
Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients.Biophys Chem. 2017 Nov;230:89-98. doi: 10.1016/j.bpc.2017.08.011. Epub 2017 Sep 1. Biophys Chem. 2017. PMID: 28916410 Free PMC article.
-
Nephrotoxic potential of Bence Jones proteins.N Engl J Med. 1991 Jun 27;324(26):1845-51. doi: 10.1056/NEJM199106273242603. N Engl J Med. 1991. PMID: 1904132
-
Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL-amyloidosis.Biochemistry. 1992 Mar 31;31(12):3265-72. doi: 10.1021/bi00127a031. Biochemistry. 1992. PMID: 1554711
-
Tetramer Bence Jones protein in the immunoproliferative diseases. Angioimmunoblastic lymphadenopathy, primary amyloidosis, and multiple myeloma.Am J Clin Pathol. 1989 Jun;91(6):639-46. doi: 10.1093/ajcp/91.6.639. Am J Clin Pathol. 1989. PMID: 2499179 Review.
-
[Current status regarding detection of monoclonal component in Japan].Rinsho Byori. 2010 Apr;58(4):397-400. Rinsho Byori. 2010. PMID: 20496769 Review. Japanese.
Cited by
-
Systemic amyloidoses.Annu Rev Biochem. 2013;82:745-74. doi: 10.1146/annurev-biochem-072611-130030. Epub 2013 Feb 28. Annu Rev Biochem. 2013. PMID: 23451869 Free PMC article. Review.
-
The FLC dimer with lambda type may false-migrate to the position of "albumin" band by urine protein electrophoresis on Sebia agarose gel-based detection system.J Clin Lab Anal. 2019 Feb;33(2):e22658. doi: 10.1002/jcla.22658. Epub 2018 Aug 27. J Clin Lab Anal. 2019. PMID: 30152095 Free PMC article.
-
Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al).PLoS One. 2012;7(6):e38061. doi: 10.1371/journal.pone.0038061. Epub 2012 Jun 18. PLoS One. 2012. PMID: 22723846 Free PMC article.
-
Calorimetric Markers for Detection and Monitoring of Multiple Myeloma.Cancers (Basel). 2022 Aug 11;14(16):3884. doi: 10.3390/cancers14163884. Cancers (Basel). 2022. PMID: 36010876 Free PMC article. Review.
-
Immunoglobulin light chain amyloid aggregation.Chem Commun (Camb). 2018 Sep 20;54(76):10664-10674. doi: 10.1039/c8cc04396e. Chem Commun (Camb). 2018. PMID: 30087961 Free PMC article. Review.
References
-
- Roussel A, Spinelli S, Deret S, Navaza J, Aucouturier P, Cambillau C. The structure of an entire noncovalent immunoglobulin kappa light-chain dimer (Bence-Jones protein) reveals a weak and unusual constant domains association. Eur J Biochem. 1999;26:192–199. - PubMed
-
- Gertz MA, Lacy MQ, Dispenzieri A, Amyloidosis Hematol Oncol Clin North Am. 1999;13:1211–1233. - PubMed
-
- Sezer O, Eucker J, Schmid P, Possinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol. 2000;79:1–6. - PubMed
-
- Roye B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int. 2004;65:642–648. - PubMed
-
- Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem. 1997;50:183–242. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical